Long-term survival after salvage pemetrexed for refractory primary T-cell lymphoma of the CNS
Primary T-cell CNS lymphoma is a rare and aggressive malignancy. High-dose methotrexate (MTX) based chemotherapy regimens are used as standard first-line treatment, followed by consolidative strategies to improve the duration of response. Although MTX-based therapy has been shown to be efficacious,...
| 出版年: | CNS Oncology |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | 論文 |
| 言語: | 英語 |
| 出版事項: |
Taylor & Francis Group
2023-09-01
|
| 主題: | |
| オンライン･アクセス: | https://www.futuremedicine.com/doi/10.2217/cns-2022-0021 |
| 要約: | Primary T-cell CNS lymphoma is a rare and aggressive malignancy. High-dose methotrexate (MTX) based chemotherapy regimens are used as standard first-line treatment, followed by consolidative strategies to improve the duration of response. Although MTX-based therapy has been shown to be efficacious, treatment options for MTX-refractory disease are not well-defined. Here, we report a case of a 38-year-old man with refractory primary T-cell CNS lymphoma who demonstrated a complete response to pemetrexed treatment. He subsequently received conditioning chemotherapy consisting of thiotepa, busulfan and cyclophosphamide followed by autologous stem cell transplantation. The patient continues to remain recurrence-free to date at 9 years post-treatment. |
|---|---|
| ISSN: | 2045-0907 2045-0915 |